Search Results | Blood | American Society of Hematology

1-20 of 44

2 3

Sort by

Sort Order Select

Journal Articles

Comparing Survival Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Nodal Peripheral T-Cell Lymphoma

Yumeng Zhang, Jennifer Eatrides, Ashley Rose, Ling Zhang, Farhad Khimani, Aleksandr Lazaryan, Bijal D. Shah, Hayder Saeed, Michael D. Jain, Hien D. Liu, Frederick L. Locke, Javier Pinilla Ibarz, Jongphil Kim, Mohamed A. Kharfan-Dabaja, Ernesto Ayala, Lubomir Sokol, Taiga Nishihori

Blood (2022) 140 (Supplement 1): 10634–10636.

DOI: https://doi.org/10.1182/blood-2022-169200

Published: 2022

Journal Articles

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Interim Analysis of Phase II Study

Rachid C. Baz, Jongphil Kim, Christine Sam, Brandon J. Blue, Sonila Toska, Aaron Collier, Jason Brayer, Ariel F Grajales-Cruz, Melissa Alsina, Ariosto Siqueira Silva, Kenneth H. Shain

Blood (2022) 140 (Supplement 1): 7313–7314.

DOI: https://doi.org/10.1182/blood-2022-159164

Published: 2022

Journal Articles

Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma

Taiga Nishihori, Doris K. Hansen, Hien D. Liu, Omar Alexis Castaneda Puglianini, Ciara L. Freeman, Brandon J. Blue, Jason Brayer, Jongphil Kim, Ariel F Grajales-Cruz, Jose Ochoa, Rachid C. Baz, Kenneth H. Shain, Frederick L. Locke, Melissa Alsina

Blood (2022) 140 (Supplement 1): 5174–5176.

DOI: https://doi.org/10.1182/blood-2022-171117

Published: 2022

Journal Articles

Autologous Hematopoietic Cell Transplant Consolidation for First Response Is Associated with Longer Survival in Patients with Nodal Peripheral T-Cell Lymphoma

Yumeng Zhang, Ashley Rose, Jennifer Eatrides, Hayder Saeed, Bijal D. Shah, Aleksandr Lazaryan, Farhad Khimani, Javier Pinilla Ibarz, Hien D. Liu, Frederick L. Locke, Michael D. Jain, Mohamed A. Kharfan-Dabaja, Jongphil Kim, Ling Zhang, Ernesto Ayala, Taiga Nishihori, Lubomir Sokol

Blood (2022) 140 (Supplement 1): 6569–6570.

DOI: https://doi.org/10.1182/blood-2022-168347

Published: 2022

Journal Articles

Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Blood (2022) 140 (Supplement 1): 886–888.

DOI: https://doi.org/10.1182/blood-2022-168175

Published: 2022

Journal Articles

Similar Risk of Relapse and Survival with Post-Transplant Cyclophosphamide Compared to Standard Gvhd Prophylaxis after Allogeneic Hematopoietic Cell Transplantation for AML and MDS

Hassaan Yasin, Mahrukh Naqvi, Jongphil Kim, Rawan Faramand, Omar Alexis Castaneda Puglianini, Farhad Khimani, Aleksandr Lazaryan, Taiga Nishihori, Michael Nieder, Joseph Pidala, Nelli Bejanyan

Blood (2022) 140 (Supplement 1): 4886–4888.

DOI: https://doi.org/10.1182/blood-2022-170696

Published: 2022

Journal Articles

Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience

Taiga Nishihori, Ciara L. Freeman, Doris K. Hansen, Brandon J. Blue, Omar Alexis Castaneda Puglianini, Jongphil Kim, Ariel F. Grajales-Cruz, Jason Brayer, Jose Ochoa, Hien D. Liu, Kenneth H. Shain, Rachid C. Baz, Frederick L. Locke, Melissa Alsina

Blood (2022) 140 (Supplement 1): 4856–4858.

DOI: https://doi.org/10.1182/blood-2022-168888

Published: 2022

Journal Articles

Immune Profiles of Myeloma Tumor Microenvironment May Predict Sensitivity or Resistance to Elotuzumab

David Noyes, Melissa Alsina, Kenneth H. Shain, Rachid Baz, Taiga Nishihori, Jose Ochoa, Jinming Song, Jongphil Kim, Alexandra Achille, Jason Brayer

Blood (2021) 138 (Supplement 1): 2682.

DOI: https://doi.org/10.1182/blood-2021-151922

Published: 2021

Journal Articles

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Joseph Pidala, MD, Kelly Walton, Hany Elmariah, MDMS, Jongphil Kim, PhD, Asmita Mishra, MD, Nelli Bejanyan, MD, Taiga Nishihori, MD, Farhad Khimani, MBBS, Lia Perez, MD, Rawan Faramand, MD, Marco L. Davila, MD PhD, Michael Nieder, MD, Nicholas Lawrence, PhD, Harshani Lawrence, PhD, Claudio Anasetti, MD, Said Sebti, PhD, Brian C. Betts, MD

Blood (2020) 136 (Supplement 1): 48–49.

DOI: https://doi.org/10.1182/blood-2020-133874

Published: 2020

Journal Articles

Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome

Blood (2019) 134 (Supplement_1): 4621.

DOI: https://doi.org/10.1182/blood-2019-130922

Published: 2019

Journal Articles

CD34+ Cell Dose Influences Survival after Allogeneic Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Hany Elmariah, MD MS, Syeda Mahrukh Hussnain Naqvi, MD MHS, Jongphil Kim, PhD, Taiga Nishihori, MD, Asmita Mishra, MD, Lia Perez, MD, Hien D. Liu, MD, Farhad Khimani, MD, Michael Nieder, MD, Joseph Pidala, MD, Nelli Bejanyan, MD

Blood (2019) 134 (Supplement_1): 3329.

DOI: https://doi.org/10.1182/blood-2019-129437

Published: 2019

Journal Articles

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

Taiga Nishihori, MD, Rachid Baz, MD, Leonel Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Frederick L. Locke, MD, Jongphil Kim, PhD, Jinming Song, MD PhD, Michael Dumala, Melissa Alsina, MD

Blood (2019) 134 (Supplement_1): 3189.

DOI: https://doi.org/10.1182/blood-2019-131451

Published: 2019

Journal Articles

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Taiga Nishihori, MD, Melissa Alsina, MD, Jose Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Rachid Baz, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Jongphil Kim, PhD, Michael Dumala, Joel G. Turner, PhD, Daniel M Sullivan, MD

Blood (2019) 134 (Supplement_1): 3314.

DOI: https://doi.org/10.1182/blood-2019-131321

Published: 2019

Journal Articles

Effect of NPM1 Mutation on Prognosis and Therapeutic Efficacy in Patients Aged ≥70 Years with Acute Myeloid Leukemia

Chetasi Talati, MD, Andrew Kuykendall, MD, Najla Al Ali, M.Sc, Jongphil Kim, Marina Sehovic, Kenneth S. Zuckerman, MD, David A Sallman, MD, Alan F. List, MD, Eric Padron, MD, Rami S. Komrokji, MD, Benjamin Djulbegovic, MD, Martine Extermann, MD, Kendra Sweet, MD, Jeffrey E. Lancet, MD

Blood (2017) 130 (Supplement 1): 2676.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.2676.2676

Published: 2017

Journal Articles

Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)

Rachid Baz, MD, Jeffrey A Zonder, MD, Kenneth H Shain, MD PhD, Melissa Alsina, MD, Jason B. Brayer, PhDMD, Mark Melody, Joel G. Turner, PhD, Jana L Dawson, Jongphil Kim, Daniel M Sullivan, MD

Blood (2017) 130 (Supplement 1): 3095.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.3095.3095

Published: 2017

Journal Articles

Outcomes in Older Adults (age ≥ 70) with Acute Myeloid Leukemia Based on Choice of Frontline Treatment for Proliferative or Non-Proliferative Phenotype

Chetasi Talati, MD, Andrew Kuykendall, MD, Najla Al Ali, M.Sc, Jongphil Kim, Marina Sehovic, Kenneth S. Zuckerman, MD, David A Sallman, MD, Alan F List, MD, Eric Padron, MD, Rami S. Komrokji, MD, Benjamin Djulbegovic, MD, Martine Extermann, MD, Kendra Sweet, MD, Jeffrey E. Lancet, MD

Blood (2017) 130 (Supplement 1): 1412.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.1412.1412

Published: 2017

Journal Articles

Negative Impact of FLT3-ITD Mutation in Elderly Acute Myeloid Leukemia Patients (Age ≥70) Is Karyotype Dependent

Blood (2017) 130 (Supplement 1): 1413.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.1413.1413

Published: 2017

Journal Articles

Hypomethylating Agents Versus Intensive Chemotherapy in Elderly Patients (Age ≥ 70) with Acute Myeloid Leukemia with High White Blood Cell Count

Chetasi Talati, MD, Andrew Kuykendall, MD, Najla Al Ali, M.Sc, Jongphil Kim, Marina Sehovic, Kenneth S. Zuckerman, MD, David A Sallman, MD, Eric Padron, MD, Alan F. List, MD, Rami S. Komrokji, MD, Benjamin Djulbegovic, MD, Martine Extermann, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD

Blood (2017) 130 (Supplement 1): 3911.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.3911.3911

Published: 2017

Journal Articles

Comparison of Survival Outcomes in Elderly Acute Myeloid Leukemia Patients (Age ≥ 70) When Treated with Azacitidine or Decitabine As an Initial Treatment Modality

Blood (2017) 130 (Supplement 1): 3912.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.3912.3912

Published: 2017

Journal Articles

Type of Therapy May Influence Outcomes in Patients over Age 70 with Acute Myeloid Leukemia: A Systematic Review of More Than 11,000 Patients

Martine Extermann, MD PhD, Marina Sehovic, MD MPH, Tea Reljic, MPH, Jongphil Kim, PhD, Jeffrey E. Lancet, MD, Benjamin Djulbegovic, MD PhD

Blood (2016) 128 (22): 3998.

DOI: https://doi.org/10.1182/blood.V128.22.3998.3998

Published: 2016

2 3

NARROW

Comparing Survival Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Nodal Peripheral T-Cell Lymphoma

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Interim Analysis of Phase II Study

Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma

Autologous Hematopoietic Cell Transplant Consolidation for First Response Is Associated with Longer Survival in Patients with Nodal Peripheral T-Cell Lymphoma

Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Similar Risk of Relapse and Survival with Post-Transplant Cyclophosphamide Compared to Standard Gvhd Prophylaxis after Allogeneic Hematopoietic Cell Transplantation for AML and MDS

Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience

Immune Profiles of Myeloma Tumor Microenvironment May Predict Sensitivity or Resistance to Elotuzumab

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome

CD34+ Cell Dose Influences Survival after Allogeneic Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Effect of NPM1 Mutation on Prognosis and Therapeutic Efficacy in Patients Aged ≥70 Years with Acute Myeloid Leukemia

Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)

Outcomes in Older Adults (age ≥ 70) with Acute Myeloid Leukemia Based on Choice of Frontline Treatment for Proliferative or Non-Proliferative Phenotype

Negative Impact of FLT3-ITD Mutation in Elderly Acute Myeloid Leukemia Patients (Age ≥70) Is Karyotype Dependent

Hypomethylating Agents Versus Intensive Chemotherapy in Elderly Patients (Age ≥ 70) with Acute Myeloid Leukemia with High White Blood Cell Count

Comparison of Survival Outcomes in Elderly Acute Myeloid Leukemia Patients (Age ≥ 70) When Treated with Azacitidine or Decitabine As an Initial Treatment Modality

Type of Therapy May Influence Outcomes in Patients over Age 70 with Acute Myeloid Leukemia: A Systematic Review of More Than 11,000 Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only